Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis.
Fiche publication
Date publication
juillet 2018
Journal
Clinical nuclear medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel, Pr MALOUF Gabriel
Tous les auteurs :
Imperiale A, Latgé A, Schaff-Wendling F, Goichot B, Kurtz JE, Malouf GG
Lien Pubmed
Résumé
We report the results of serial F-FDG PET/CT investigations in a 49-year-old woman presenting with an advanced cecal high-grade neuroendocrine carcinoma harboring a somatic BRAF mutation. Patient was refractory to standard chemotherapy regimen showing life-threatening hyperlactatemia. Early after the beginning of BRAF-MEK therapy (dabrafenib and trametinib), impressive improvement in PET/CT imaging was achieved. The pathological F-FDG uptake in cecal primary tumor as well as in nodal, hepatic, and bone metastases drastically decreased. Moreover, the reduction of total lesion glycolysis on PET/CT images was strictly related to extraordinary patient clinical response and lactic acid level normalization.
Mots clés
Acidosis, Lactic, complications, Carcinoma, Neuroendocrine, diagnostic imaging, Combined Modality Therapy, Female, Humans, Imidazoles, therapeutic use, Middle Aged, Mitogen-Activated Protein Kinase Kinases, metabolism, Molecular Targeted Therapy, Mutation, Oximes, therapeutic use, Positron Emission Tomography Computed Tomography, Proto-Oncogene Proteins B-raf, genetics, Pyridones, therapeutic use, Pyrimidinones, therapeutic use, Treatment Outcome
Référence
Clin Nucl Med. 2018 Jul 21;: